Conversely, the IC50 values of five drugs, including GSK1904529A_1093, Gefitinib_1010, Crizotinib_1083, Dabrafenib_1373 and KRAS (G12C) Inhibitor-12_1855 were significantly higher in circulating MAPS-low group than that in MAPS-high group (Fig. 6D–H), suggesting that NSCLC patients with high circulating MAPS may benefit more from these drugs. This evidence concerns the gene C3orf62 and non-small cell lung carcinoma.